Immunitas is an immuno-oncology therapeutics company advancing multiple programs to the clinic. Immunitas’ programs are derived from a cross-functional, highly integrated, single cell genomics platform that enables rapid target identification and validation in parallel with antibody discovery and engineering. IMT-009, a first-in-class T & NK cell modulator targeting CD161, is being developed for the treatment of solid tumors and hematological malignancies. The company was founded with leading scientists from Dana Farber, MGH, the Broad, and MIT. In 2019, Immunitas raised a $39M Series A from a strong syndicate of investors including the Longwood Fund, Hillhouse, NVF, Leaps by Bayer, and M Ventures.
View Top Employees from Immunitas Therapeutics| Website | https://www.immunitastx.com/ |
| Employees | 39 (39 on RocketReach) |
| Founded | 2019 |
| Address | 21 Hickory Dr, Waltham, Massachusetts 02451, US |
| Industry | Biotechnology, Biotechnology Research, Science and Engineering, Drug Discovery |
Looking for a particular Immunitas Therapeutics employee's phone or email?
Immunitas Therapeutics Questions
Alison Tisdale is the Senior Director, Antibody Discovery and Engineering of Immunitas Therapeutics.
39 people are employed at Immunitas Therapeutics.
Immunitas Therapeutics is based in Waltham, Massachusetts.
Top Immunitas Therapeutics Employees
-
33
-
54
-
2
-
ViewMing Tang
Director of Computational Biology at Immunitas Therapeutics
Boston, Massachusetts, United States32 -
11
-
View
Shruti Malu
Director, Head of Discovery and Pharmacology at Immunitas Therapeutics
Indianapolis, Indiana, United States11
Related Companies
